# Integrating single-cell RNA-seq, bulk RNA-seq and network pharmacology reveals protective effect of salidroside in peritoneal dialysis-associated peritoneal fibrosis

## TL;DR

This study shows that salidroside may help reduce peritoneal fibrosis caused by dialysis by targeting specific pathways and proteins.

## Contribution

The study is the first to explore salidroside's therapeutic potential in peritoneal dialysis-induced fibrosis using multi-omics and pharmacology.

## Key findings

- Salidroside treatment reduced collagen deposition and fibrosis markers in a mouse model of peritoneal fibrosis.
- Four key therapeutic targets for salidroside were identified: cathepsin S, VDR, plasminogen activator urokinase, and galectin 3.
- Salidroside may inhibit extracellular matrix deposition by upregulating VDR expression.

## Abstract

Salidroside (2- (4-Hydroxyphenyl) ethyl β-D-glucopyranoside, SAL) is a bioactive compound present in Rhodiola rosea L., exhibiting diverse pharmacological properties such as anti-inflammatory and anti-fibrotic effects. Despite its known benefits, the therapeutic potential of SAL in peritoneal dialysis (PD) -induced peritoneal fibrosis remains unexplored. This study aims to investigate the protective effects of SAL in PD-related peritoneal fibrosis and its underlying mechanisms through the integration of single-cell RNA-seq, bulk RNA-seq, and network pharmacology analyses. A total of 249 disease targets were identified through single-cell RNA-seq and bulk RNA-seq analyses. Functional enrichment analysis highlighted the involvement of extracellular matrix organization, neutrophil degranulation, and the vitamin D receptor (VDR) pathway in peritoneal fibrosis. By intersecting 148 drug targets with the 249 disease targets, four therapeutic targets for SAL treatment against peritoneal fibrosis were pinpointed: cathepsin S, VDR, plasminogen activator urokinase, and galectin 3. In a murine model of peritoneal fibrosis induced by intraperitoneal injection of 4.25% PD fluid, SAL treatment significantly mitigated peritoneal fibrosis, as evidenced by reduced collagen deposition, decreased protein expression of α-smooth muscle actin and Collagen I, and a thinner peritoneum. In vitro experiments demonstrated that SAL treatment inhibited extracellular matrix deposition, potentially through upregulation of VDR expression. In conclusion, SAL may target VDR domains as a therapeutic agent for PD-related peritoneal fibrosis. These findings comprehensively identify potential therapeutic targets for SAL in combating peritoneal fibrosis, providing a theoretical basis for the clinical application of SAL in the treatment of peritoneal fibrosis.